Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. (Nasdaq Global Select Market: PIPE) is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for neuroscience, inflammation and immunology indications with significant unmet medical need. The company pioneers a clinical translational approach targeting… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Contineum Therapeutics, Inc. does
In the company’s own words
Contineum Therapeutics, Inc. (Nasdaq Global Select Market: PIPE) is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for neuroscience, inflammation and immunology indications with significant unmet medical need. The company pioneers a clinical translational approach targeting biological pathways associated with specific clinical impairments to alter the course of disease.
Contineum's lead asset is PIPE-791, a novel brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor that the company is developing for idiopathic pulmonary fibrosis and chronic pain conditions including osteoarthritic pain and chronic low back pain. The company completed a Phase 1 healthy volunteer trial and a Phase 1b positron emission tomography trial measuring the relationship between pharmacokinetics and receptor occupancy. In December 2025, Contineum initiated a Phase 2 trial called PROPEL-IPF, a 26-week randomized, double-blind, placebo-controlled global clinical trial expected to enroll approximately 324 subjects to evaluate efficacy, safety and tolerability of PIPE-791 in IPF patients. The company also completed enrollment in a Phase 1b chronic pain trial and anticipates top-line data in the second quarter of 2026.
The company's second drug candidate, PIPE-307, is a selective small-molecule inhibitor of the muscarinic type 1 receptor in development for depression and relapse-remitting multiple sclerosis through a collaboration with Johnson & Johnson. Contineum completed two Phase 1 trials of PIPE-307 in healthy volunteers. J&J initiated a Phase 2 trial called Moonlight-1 in December 2024 for major depressive disorder, and Contineum reported top-line data from a Phase 2 VISTA trial for RRMS in November 2025.
Contineum retains worldwide rights to its LPA1R programs and discovery portfolio while partnering with J&J for PIPE-307 development and commercialization. The company is a smaller reporting company and emerging growth company. As of February 27, 2026, Contineum had 37,336,036 total shares outstanding. More information is available at the company's website.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1855175
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Contineum Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Contineum Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Contineum Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Contineum Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Contineum Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”